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Herba epimedii (HEP) is one of the most frequently used herbs prescribed for treatment of osteo-
porosis in China. In the present study, the in vivo effects of HEP extract on bone metabolism
were evaluated using 4-month-old ovariectomized (OVX) or sham-operated (Sham) female Sprague-
Dawley rats orally administered with HEP extract (110 mg kg1d1), 17ß-estrogen (2 mg kg1d1)
or its vehicle for 3 months. HEP extract significantly decreased urinary calcium excretion, suppressed
serum alkaline phosphatase (ALP) activity and urinary deoxypyridinoline levels in OVX rats
(P< 0.05 versus vehicle-treated OVX rats). Histomorphometric analysis indicated that HEP extract
could prevent OVX-induced bone loss by increasing tibial trabecular bone area and decreasing tra-
becular separation in OVX rats (P< 0.05 versus vehicle-treated OVX group). The in vitro effects of
HEP extract were also studied using rat osteoblast-like UMR 106 cells. HEP extract significantly
stimulated cell proliferation in a dose-dependent manner (P< 0.01 versus vehicle-treated) and
increased ALP activity at 200 mg ml1 (P< 0.01 versus vehicle-treated) in UMR 106 cells. It modu-
lated osteoclastogenesis by increasing osteoprotegrin (OPG) mRNA and decreasing receptor activ-
ator of NF-kB ligand (RANKL) mRNA expression, resulting in a dose-dependent increase in
OPG/RANKL mRNA ratio (P< 0.01 versus vehicle-treated). Taken together, HEP treatment can
effectively suppress the OVX-induced increase in bone turnover possibly by both an increase in
osteoblastic activities and a decrease in osteoclastogenesis. The present study provides the evidence
that HEP can be considered as a complementary and alternative medicine for treatment of post-
menopausal osteoporosis.
Keywords: Herba Epimedium – osteoblast-like UMR 106 cells – osteoclastogenesis – osteoporosis –
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Introduction
Chinese herbal medicine has been widely used for thousands
of years for the treatment of fractures and joint diseases. The
aerial part of Herba epimedii (HEP) is commonly used in tra-
ditional Chinese medicine for ‘strengthening the kidney’ (1,2).
Based on theories of Chinese medicine, the kidney (different
from the organ kidney in a modern sense) is responsible for
the nourishment of bone and supports gonadal functions. Her-
bal formulas classified as kidney-tonifying are thus tradition-
ally used in cases of bone diseases and gonadal dysfunction.
Eight of the 16 species of the Epimedium genus have been
used for centuries in traditional Chinese herbal formulations
to treat a wide range of diseases, including osteoporosis (3).
For reprints and all correspondence: Man-SauWong, Department of Applied
Biology and Chemical Technology, The Hong Kong Polytechnic University,
Hong Kong SAR, China. Tel: þ852-27666695; Fax: þ852-23649932;
E-mail: bcmswong@polyu.edu.hk
*Correspondence may also addressed to: yaoxinsheng@hotmail.com
 The Author (2005). Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety
but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oupjournals.org
In the past, the development of herbal anti-osteoporosis formu-
las was pursued mainly by scientists in Asian countries, includ-
ing China, Japan and Korea (4–6). However, as a result of
recent evidence that estrogen replacement therapy (ERT) is
associated with increased risk of breast, ovarian and endo-
metrial cancer in postmenopausal women (7,8), it is now gen-
erally recognized that alternative approaches to the prevention
and treatment of osteoporosis might be worth exploring.
HEP is one of the most frequently used herbs in formulas
that are prescribed for the treatment of osteoporosis in China
(9). Over the years, numerous scientific studies have been car-
ried out in China on the in vivo as well as in vitro effects of this
herb on bone and mineral metabolism. However, these studies
have been largely inaccessible to international scholars since
they were published in Chinese-language journals. Previous
studies by various scientists in China have repeatedly shown
that HEP extract, either as a single herbal extract or in a com-
posite formula, could reduce bone loss in an ovariectomized
(OVX) rat model (2,10–13) as well as in aged (14) or other
rat (15,16) models. A short-term clinical study involving
postmenopausal women (1) has also demonstrated that HEP
extract could prevent bone loss and increase osteocalcin and
E2 levels. In addition, the total flavonoid fraction of HEP can
improve bone mineral density, enhance the E2 level and
decrease the circulating IL-6 level in OVX rats (13). In vitro
experiments showed that the flavonoid fraction of HEP could
promote cell proliferation and increase alkaline phosphatase
(ALP) activity in primary rat calvarial osteoblasts (17–19).
With the recent discovery of the receptor activator of NF-kB
ligand (RANKL)–RANK interaction, the role of osteoblasts in
osteoclast differentiation is now clearly defined (20–23). The
binding of RANKL (the membrane-associated factor) on
osteoblastic cells to RANK on the osteoclast cell surface
results in the induction of osteoclast function. At the same
time, the secretion of osteoprotegrin (OPG, the soluble decoy
receptor of RANKL) (20,21,24) by osteoblasts can interfere
with RANKL–RANK interactions, thereby modulating
osteoclastogenesis. Thus, the effects of HEP on the expression
of RANKL and OPG mRNA in UMR 106 cells can be studied
to assess its potential effects on osteoclastogenesis.
In the present study, we aimed to systematically evaluate the
in vivo and in vitro effect of HEP extract on bone and mineral
metabolism. This study is designed to demonstrate the efficacy
of using HEP extract in the treatment of osteoporosis as well as
to delineate its molecular actions in modulating osteoblastic
and osteoclastic activities.
Methods
Preparation of Crude Extracts of HEP
The dry aerial part of Epimedium brevicornum Maxim was
purchased from Shenyang Northeast Drugstore and authentic-
ated by Prof. Zerong Jiang, Shenyang Pharmaceutical Univer-
sity. It was extracted with boiling water three times. The
decoction was then concentrated and spray-dried, giving a
yield of extraction of 10%. Analysis of the chemical com-
position of HEP found that flavonol glycosides, especially
icarrin, were the major and active components (3,25–27).
The flavonoid components of crude extract powder were
analyzed according to the method given in the Chinese medi-
cine pharmacopoeia (28). The standard solution contains
10 mg ml1 of icarrin. Total flavonoid content was 9.6 ±
0.3% of HEP crude extract. An HPLC spectrum of the HEP
extract is shown in Fig. 1.
Animal Study
A total of 35 virgin Sprague–Dawley specific-pathogen-free
(SPF) female rats (Laboratory Animal Center, Guangzhou
University of Traditional Chinese Medicine) were used in
this study. The rats were 3 months old upon arrival, and
4 months old upon the commencement of herbal treatment.
The rats were housed in cages under a 12 h light/12 h dark
cycle at 22C. Deionized water was provided to the animals
ad libitum. During the study, OVX rats were pair-fed with nor-
mal diet based on the average weekly food consumption of the
sham control group. The animals were weighed at bi-weekly
intervals throughout the study period. Husbandry of the ani-
mals was based on the Guide for Care and Use of Laboratory
Animals (29).
The animals were either sham-operated (sham, n ¼ 8) or
ovariectomized (OVX, n ¼ 27). The OVX rats were randomly
divided into three groups: vehicle treated (OVX, n ¼ 8);
estrogen treated (E2, n ¼ 10); and HEP extract treated (HEP,
n ¼ 9). The animals were monitored for 4 weeks before initi-
ation of the therapeutic regime to allow them to recover from
the operation. HEP extract powder was dissolved in deionized
distilled water and was orally administered to rats at a dosage
of 110 mg kg1 d1 for 3 months. The dosage of HEP for
rats in this study was determined based on the dosage used in
clinical trials and calculated using the dose conversion table
between human and rats. Oral E2 treatment was given at a dos-
age of 2 mg kg1 d1 for 3 months. Twenty-four hour urine
samples were collected using separators by placing animals
in metabolic cages during the last week. Urine samples were
acidified with 2 ml of 1 M HCl and centrifuged at 1015 g for
10 min at 4C to remove contaminating sediments; aliquots
were stored at 20C until they were assayed. After 3 month
herbal treatments, the rats were killed under deep ether anes-
thesia, blood samples were collected and the uteri were
weighed. Blood samples were allowed to clot at room temper-
ature and the serum was separated by centrifuging at 1015 g for
20 min. Serum samples were stored at 70C until analysis.
Left femora and tibias were removed and wrapped in gauze
saturated with physiological saline and stored at 20C
until use.
Biochemical Analysis of Serum and Urine Samples
The calcium (Ca) and phosphorus (P) concentrations of both
serum and urine samples were measured using standard colori-
metric methods with commercial kits (ZhongSheng BeiKong
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Bio-technology and Science Inc., China) and analyzed using
an automatic analyzer (ALCYON 300i, Abbott Laboratories
Ltd, USA). Urinary creatinine (Cr) was determined using the
picric acid method (commercial kit from Shanghai KeHua
DongLing Diagnostic Products Company Ltd, China). ALP
activity was determined using a commercial ALP kit (Zhong-
Sheng BeiKong Bio-technology and Science Inc., China).
Urine deoxypyridinoline (DPD) level was assayed using a rat
DPD enzyme-linked immunosorbent assay (ELISA) kit
(Quidel Corporation, San Diego, CA, USA). The urinary Ca
excretion rate was expressed as the ratio of urinary Ca to Cr
level (Ca/Cr), and urinary DPD levels were expressed as the
ratio of urinary DPD to Cr level (DPD/Cr).
Bone Histomorphometric Measurement
Left tibias were collected, cleaned by removal of adherent
tissue and fixed in chloroform. Upon fixation, diaphyseal seg-
ments of the tibias were dehydrated, defatted in acetone
followed by ether and then embedded in bioplastic. The blocks
were sectioned at a thickness of 5 mm with a Reichert–Jung
supercut microtome (Reichert–Jung, Heidelberg, Germany)
and digitized using a Leica camera (MPS60, Leica Micro-
systems Welzlar GmbH, Bensheim, Germany). Sections
containing the tibio-fibular junction were coupled to an
Olympus AH-2 microscope (Olympus Corporation, Japan)
and were determined using the Leica QW 550 image software
(Leica, Bensheim, Germany). Cancellous bone was measured
in the proximal tibial metaphysis at a standard sampling
site in the secondary spongiosa, as described previously
(30,31). Structural variables such as total tissue area (TV),
trabecular area (TbAr) and trabecular bone surface (BS) were
measured in the spongiosa within a conventional visual field
window whose upper side was centered 1 mm below the
growth plate–metaphyseal junction. TbAr% refers to the
percentage of trabecular bone area within total tissue (meta-
physeal) area. The trabecular thickness and separation were
calculated according to structural variables, as previously
described (32).
Culture of Rat Osteoblast-like UMR 106 Cells
UMR 106 cells (ATCC no. CRL-1661) were routinely cultured
in Dulbecco’s modified Eagle medium (DMEM) supplemen-
ted with 5% fetal bovine serum (FBS), penicillin 100 U ml1
and streptomycin 100 mg ml1. DMEM, FBS and penicillin–
streptomycin–glutamine were purchased from Life Technolo-
gies Inc. (Carlsbad, CA, USA). At 80% confluence, cells
were seeded in a 96-well microtiter plate (Falcon, Becton-
Dickison Franklin hakes, USA) or 24-well or 6-well plates at
a density of 2500, 100 000 or 200 000 cells per well, respect-
ively. Upon confluence, the culture medium was switched to
serum-free DMEM for another 24 h. Cells were then treated
with HEP extract at 50, 100 and 200 mg ml1 for 24 or 48 h.
HEP extract was prepared by dissolving 20 mg of total HEP
extract in 1 ml deionized distilled water and diluting with
DMEM to achieve the final concentration. Cells were cultured
at 37C in a humidified atmosphere of 95% air and 5% CO2.
Cell Proliferation Assay
The 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bro-
mide (MTT; Amersham Pharmacia Biotech, Little Chalfont,
UK) assay was used as an indirect measure of growth, as
Figure 1. Reverse-phase HPLC for the quantification of icarrin in HEP. The mobile phase was MeOH:H2O ¼ 55:45 at 1 ml min1. Peaks eluting at 18.5 min are
icarrin.
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described previously (33). Briefly the medium was removed
and replaced with 100 ml of MTT reagent (5 mg ml1) in
PBS. The plates were incubated for 4 h at 37C, and 100 ml
DMSO was added to dissolve formazan crystals. The
multi-well plates were shaken for 15 min and the signals
were detected using a POLARstar Galaxy spectrophotometer
(BMG Labtechnologies GmbH, Germany) at a wavelength of
570 nm. The results of the MTT assay were expressed as cell
numbers upon conversion of absorbance into cell numbers
using a calibration curve. The calibration curve was prepared
by seeding an assigned number of UMR 106 cells into a
96-well plate for 24 h before adding MTT solution.
ALP Activity Assay
Cells were washed with ice-cold PBS and scraped in 10 nM of
Tris–HCl solution containing 2 mM of MgCl2 and 0.05%
TritonX-100, pH 8.2. The cell suspension was sonicated on ice.
Aliquots of supernatants were subjected to protein assay using
a Bio-Rad kit (Hercules, CA, USA) according to Bradford’s
method, and ALP activity was measured using commercial
ALP reagent (StarbioLaboratory, Sigma, Texas, USA). Briefly,
the assay mixture containing 16 mM of p-nitrophenyl phos-
phate in 350 mM aminomethyl propanol AMPbuffer, pH
10.5, supplemented with 2 mM of MgCl2 was incubated at
37C. The amount of p-nitrophenol liberated was measured
using an ALCYON Analyzer (ALCYON 300i, Abbott
Laboratories, USA).
RNA Extraction and RT–PCR
Total RNA was isolated from cells cultured in a 6-well plate
using TRIzol reagent according to the manufacturer’s instruc-
tions (Life Technologies Inc., Carlsbad, CA, USA). Total
RNA (2 mg) was used to generate cDNA in each sample using
SuperScript II reverse transcriptase (Invitrogen Corporation,
Carlsbad, CA, USA) with 0.5 mg oligo(dT)15 primers. One
microliter of total cDNA was amplified in each PCR reaction
mixture containing 0.5 mM of sense and antisense primers
(Genemed Synthesis, Inc., South San Francisco, CA, USA) of
selected genes (Table 1). The PCR reaction mixture (in a total
volume of 20 ml) contained 1· Taq reaction buffer, 0.2 mM
of deoxynucleoside triphosphate (dNTP), 1.5 mM of MgCl2,
0.5 mM of each primer and 0.5 U of Taq DNA polymerase
(Invitrogen Corporation, Carlsbad, CA, USA). PCR amplifica-
tion was performed on a GeneAmp 9600 PCR system (Perkin
Elmer, Foster City, CA, USA). The PCR was carried out as fol-
lows: denaturation program (94C, 4 min), amplification for
30 cycles (94C for 30 s; 55C for 30 s; and 72C for 60 s)
and final extension at 72C for 7 min. The PCR products were
analyzed using agarose gel electrophoresis. Optical densities
of ethidium bromide-stained DNA bands were quantified using
Bio-Rad image scanning software and the mRNA expression
levels were normalized to the expression of a housekeeping
gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Statistical Analysis
Data are reported as mean ± SEM. Data were statistically ana-
lyzed by one-way analysis of variance (ANOVA) with the
level of significance set at P < 0.05. Critical differences
between means were evaluated by Dunnett’s multiple com-
parison test set at P < 0.05.
Results
Body Weight and Uterine Weight in OVX Rats
As shown in Fig. 2, the body weights of the OVX and sham
rats were not significantly different at the start of the study.
One month after surgery, OVX rats weighed 11% more than
sham rats (P < 0.01) despite the fact that these animals were
pair-fed the same amount of food as the sham group. The
body weight of the OVX group continued to be significantly
higher throughout the study. Treatment with E2 but not HEP
extract prevented the OVX-induced weight gain (Fig. 2A).
Uterine weight was significantly reduced in the vehicle-
treated OVX group (P < 0.05, versus sham group) (Fig. 2B).
Treatment of OVX rats with E2 but not with HEP extract
significantly stimulated the growth of the atrophic uterus
(P < 0.01, versus vehicle-treated OVX group).
Serum and Urine Biochemical Markers in OVX Rats
The effects of HEP extracts on serum and urine biochemical
markers are summarized in Table 2. OVX appeared to lower
serum Ca and P levels in rats, but the changes did not reach
statistical significance (P ¼ n.s., versus sham group); simil-
arly, treatment of OVX rats with HEP extract or E2 did not
significantly alter serum Ca and P levels. Urinary Ca levels
increased significantly in response to OVX (P < 0.05, versus
sham group). Treatment with either HEP extract or E2 preven-
ted the OVX-induced increase in urinary Ca levels (P < 0.01,
versus vehicle-treated OVX group). OVX appeared to lower
Table 1. Primers for reverse transcription–polymerase chain reaction
(RT–PCR)
Primer Sequence Product
Orientation Size
(bp)
Annealing
temperature (C)
OPG GACGAGATTGAG-
AGAACGAG
Sense 502 55
GGTGCTTGACTTT-
CTAGGTG
Antisense
RANKL TCAGGAGTTCCAG-
CTATGAT
Sense 298 55
CCATCAGCTGAAG-
ATAGTCC
Antisense
GAPDH TACATTTTGCTGAT-
GACTGG
Sense 202 55
TGAATGGTAGGAG-
CTTGACT
Antisense
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urinary P levels, but treatment of OVX rats with either HEP
extract or E2 appeared to raise urinary P levels; however,
none of these changes reached statistical significance. These
results indicate that treatment of OVX rats with either HEP
extract or E2 could reverse OVX-induced changes in Ca and
P homeostasis in these animals.
The effects of HEP extract on bone formation and bone
resorption in vivo were determined by the measurement of
ALP activity and urinary DPD (a breakdown product of colla-
gen during bone resorption) level. Serum ALP activity and
urinary DPD levels increased in response to OVX (P < 0.05,
vehicle-treated OVX group versus sham group), indicating an
increase in the bone turnover rate in OVX rats. Treatment of
OVX rats with HEP extract or E2 suppressed the increase in
serum ALP activity (P < 0.05 and P < 0.01, respectively,
versus vehicle-treated OVX group). Similarly, the increase in
urinary DPD level induced by OVX was prevented by treat-
ment with either HEP extract or E2 (P < 0.05, versus
vehicle-treated OVX group). These results suggest that treat-
ment of OVX rats with HEP extract as well as E2 can prevent
the OVX-induced increase in bone turnover rate.
Bone Architecture in Rat Tibia
The effects of HEP extract on rat trabecular bone architecture
are shown in Fig. 3 and the measured structure variables are
summarized in Table 3. As shown in Fig. 3, OVX altered the
trabecular architecture in rat tibia, but E2 or HEP extract
reduced the alteration of the trabecular architecture induced
by OVX. TbAr% decreased and trabecular separation (TbS)
increased significantly in OVX rats (P < 0.01, versus sham
group, Table 3), suggesting that OVX induced significant
loss of trabecular bone in rat tibia. Treatment of OVX rats
with either E2 or HEP extract prevented the decrease in
TbAr% and increase in TbS induced by OVX (P < 0.05, ver-
sus vehicle-treated OVX group, Table 3). The thickness of all
slides was similar (as show in Table 3) during the comparison
of trabecular bone area and trabecular separation among
groups.
Proliferation and Differentiation of Rat Osteoblast-like
UMR 106 cells
Treatment of UMR 106 cells with HEP extract for 24 or 48 h
stimulated cell proliferation in a dose-dependent manner
(Fig. 4A). HEP 100 and 200 mg ml1 significantly increased
osteoblastic cell numbers at 24 h by 1.4-fold (P < 0.01)
and 1.6-fold (P < 0.01), respectively. A similar trend was
observed at 48 h of treatment. To determine whether HEP
could alter osteoblastic cell differentiation, its effect on ALP
activity was studied. Treatment of UMR 106 cells with HEP
extract for 24 h stimulated ALP activity in a dose-dependent
manner (Fig. 4B). ALP activity in UMR 106 cells was signific-
antly increased by 1.5-fold (P < 0.01) with 200 mg ml1 HEP
extract. These results indicate that HEP extract can induce
UMR 106 cell proliferation and differentiation in a dose-
dependent manner.
mRNA Expression of OPG and RANKL in Rat
Osteoblast-like UMR 106 cells
As shown in Fig. 5A, HEP extract significantly increased OPG
mRNA expression in UMR 106 cells in a dose-dependent
manner (P < 0.01). On the other hand, the expression of
RANKL mRNA in these cells was significantly downregulated
by treatment with 200 mg ml1 of HEP extract (P < 0.05)
(Fig. 5B). The ratio of mRNA expression of OPG to RANKL
(OPG/RANKL) was calculated to assess its effect on osteo-
clastogenesis. As shown in Fig. 5C, the OPG/RANKL ratio in
UMR 106 cells increased when they were treated with HEP
extract at 100 mgml1 (P < 0.05) and 200 mgml1 (P < 0.01).
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Figure 2. Effect of HEP extract on body weight and uterine weight in OVX
rats. (A) Body weight was measured during the experimental period in the
sham group (diamonds), OVX group (squares) and OVX rats with oral admin-
istration of HEP extract at 110 mg kg1 d1 (open triangles) or 17-b estradiol
at 2 mg kg1 d1 (filled triangles). (B) Uterine weight was measured in the
baseline group and 4 months after operation in the sham group, OVX group,
OVX rats treated with 110 mg kg1 d1 of HEP extract and OVX rats treated
with 2 mg kg1 d1 of 17-b estradiol. Data are expressed as mean ± SEM.
*P < 0.05, **P < 0.01, versus sham control; ##P < 0.01, versus OVX group.
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The increase in OPG/RANKL ratio suggests that HEP can
inhibit osteoclastogenesis by decreasing the direct interaction
between RANKL expressed on osteoblast and RANKL
expressed on osteoclast cell surface.
Discussion
The current approach to the design of anti-osteoporotic drugs
is directed along the two basic processes of bone remodeling.
These are agents aimed at preventing bone resorption
(estrogen, calcitonin, bisphosphonates, calcium, vitamin D,
raloxifene) and agents that stimulate bone formation (fluoride,
anabolic steroids) (34). Among these, ERT used to be a pop-
ular regime for prevention and treatment of postmenopausal
osteoporosis. However, recent evidence suggests that ERT is
associated with increased risk of breast, ovarian and endo-
metrial cancer (7,8). In addition, the most frequently used
anti-osteoporotic drugs are developed in affluent countries
and the costs are too high to benefit the ordinary people in
developing or even developed countries. Thus, alternative
approaches for managing osteoporosis are needed.
HEP and other kidney-tonifying Chinese herbal medicines
have been widely used in China for thousands of years to treat
bone disease. These herbal medicines will undoubtedly con-
tinue to be used as a cost-effective alternative to commercial
pharmaceutical products by the Chinese. However, the interna-
tional acceptance of these herbal extracts as an alternative
therapeutic regime for the management of osteoporosis is
hampered by poor understanding of their actions in vivo and
in vitro, an ill-defined mechanism for their actions and their
unidentified active ingredients.
In the present study, the in vivo and in vitro effects of HEP
extract on bone and mineral metabolism were systematically
evaluated. Our results indicate that oral administration of
Table 2. Effects of HEP extract on serum and urinary biochemical markers in OVX rats
Group Dose
(mg kg1 d1)
Serum Ca
(mg l1)
Serum P
(mg l1)
Urinary Ca/Cr
(mg/mg)
Urinary P/Cr
(mg/mg)
Serum ALP
(U l1)
Urinary DPD/Cr
(nmol mg1)
Sham — 11.0 ± 0.2 3.18 ± 0.11 0.81 ± 0.13 5.65 ± 0.54 74.0 ± 10.5 4.9 ± 0.6
OVX — 10.4 ± 0.1 3.01 ± 0.08 1.35 ± 0.15* 5.22 ± 024 101. ± 9.8* 8.7 ± 0.8*
E2 2 10.8 ± 0.4 3.13 ± 0.16 0.51 ± 0.13
## 6.43 ± 1.02 48.8 ± 2.7## 6.3 ± 1.1#
HEP 110 10.7 ± 0.2 2.98 ± 0.23 0.45 ± 0.06## 5.68 ± 0.24 79.2 ± 6.9# 5.9 ± 0.9#
F-value 0.526 1.093 11.563 0.702 8.493 4.316
P >0.05 >0.05 <0.05 >0.05 <0.05 <0.05
Measurement of serum Ca, P, ALP and urinary Ca, P, DPD levels in the sham- and OVX-operated rats upon E2 and HEP treatment. The rats were orally
administrated with HEP extract (110 mg kg1 d1), 17-b estradiol (E2, 2 mg kg1 d1) or its vehicle for 3 months. Serum and urine samples were collected
and analyzed as described in ‘Methods’. Urinary Ca, P and DPD levels were corrected with the urinary Cr level and expressed as a ratio to the Cr level. Data
were expressed as mean ± SEM.
*P < 0.05; **P < 0.01, versus sham control.
#P < 0.05; ##P < 0.01, versus OVX group.
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Figure 3. Bone histomorphometric analysis of rat tibia. The images of the
metaphyseal trabeculae of the sham (A), OVX (B), E2 (C) and HEP (D) groups.
Table 3. Effect of ovariectomy, estradiol and HEP on trabecular bone
architecture in the proximal tibial metaphysis
Group Dose
(mg kg1 d1)
TbAr
(%)
TbS
(mm)
TbTh
(mm)
Sham — 40.8 ± 10.1 229.7 ± 28.8 55.8 ± 4.0
OVX — 13.8 ± 8.2** 728.5 ± 199.5** 55.3 ± 6.5
E2 2 21.0 ± 6.1
# 297.9 ± 58.5# 59.8 ± 4.1
HEP 110 20.9 ± 5.8# 396.6 ± 41.1# 56.6 ± 8.3
F-value 10.369 5.684 1.012
P <0.05 <0.05 >0.05
Measurement of trabecular bone architecture in proximal tibial metaphysis in
the sham- and OVX-operated rats upon E2 and HEP treatment. The rats were
orally administrated with HEP extract (110 mg kg1 d1), 17-b estradiol (E2,
2 mg kg1 d1) or its vehicle for 3 months. Rat tibia were collected and ana-
lyzed as described in ‘Methods’. The percentage of trabecular area (TbAr%),
trabecular separation (TbS) and trabecular thickness (TbTh) were determined.
Data were expressed as mean ± SEM.
*P < 0.05; **P < 0.01, versus sham control.
#P < 0.05; ##P < 0.01, versus OVX group.
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HEP extract for 3 months lowered serum ALP activity, urinary
Ca excretion and urinary DPD levels in OVX rats, suggesting
that HEP extract can prevent an OVX-induced increase in
bone turnover rate in rats. In addition, HEP extract could
increase trabecular bone area as well as decrease trabecular
separation in rat tibia. These osteoprotective effects were sim-
ilar to those of E2 as reported in the present study as well as in
studies by others (35). Despite the similarity of their effects in
bone, our results showed that HEP extract did not mimic the
effect of E2 on body and uterus weight. The latter is of particu-
lar interest as it indicates that HEP extract exerts its beneficial
effects on bone without inducing potentially harmful prolifer-
ative effects in reproductive tissues.
Our in vitro studies further demonstrated direct beneficial
effects of HEP extract on bone cells. It was found to stimulate
osteoblastic cell proliferation and differentiation in UMR 106
cells. These results are in agreement with both in vivo and
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Figure 5. Effect of HEP on OPG and receptor activator of NF-kB ligand
(RANKL) mRNA expression in rat osteoblast-like UMR 106 cells. UMR
106 cells were treated with 100 mg ml1 and 200 mg ml1 HEP extract or its
vehicle (ctrl) for 48 h. Total RNA was isolated and subjected to semi-
quantitative RT–PCR analysis of OPG (A) and RANKL (B) mRNA expression
under the conditions described in ‘Methods’. (C) The ratio of OPG/RANKL
was normalized by an internal control gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). Results were obtained from two independent
experiments and expressed as mean ± SEM. *P < 0.05, **P < 0.01, versus
control for n ¼ 3.
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Figure 4. Effects of HEP extracts on cell proliferation and ALP activity in rat
osteoblast-like UMR 106 cells. (A) Cell proliferation of UMR 106 cells upon
HEP extract treatment. UMR 106 cells were seeded in a 96-well plate at a dens-
ity of 2500 cells per well. After starvation for 24 h, different concentrations
(50, 100 and 200 mg ml1) of HEP extract were added, and treated for 24 or
48 h. Vehicle-treated cells served as control (ctrl). Cell number was determined
by MTT assay. Results were obtained from two independent experiments and
expressed as mean ± SEM. **P < 0.01, versus control for n ¼ 6. (B) ALP
activity of UMR 106 cells upon HEP extract treatment. UMR 106 cells were
seeded in 24-well plates at a density of 100 000 cells per well. After starvation,
50, 100 and 200 mg ml1 of HEP were added, and treated for 24 h before
ALP activity determination. Vehicle-treated cells served as control (ctrl).
The ALP activity was corrected for the amount of protein used and expressed
as U l1 mg1. Results were obtained from two independent experiments and
expressed as mean ± SEM. **P < 0.01 versus control for n ¼ 3.
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in vitro studies reported by others (5–19). In addition, our
study is the first to report that HEP extract stimulated the
expression of OPG mRNA but suppressed the expression of
RANKL mRNA in the UMR 106 cell line, resulting in a
dose-dependent increase in the OPG/RANKL ratio. These res-
ults suggest that HEP extract might inhibit osteoclastogenesis
via the modulation of the OPG/RANKL system in osteoblastic
cells.
This study was originally designed to determine whether the
HEP extract used in our in vivo study could demonstrate osteo-
protective effects in vitro, namely stimulation of osteoblastic
cell proliferation and inhibition of osteoclastogenesis via its
action on osteoblasts. However, it should be noted that limita-
tions exist in using herbal extracts for in vitro studies. The HEP
extract, which contains numerous compounds (both active and
inactive), is normally processed by the gastrointestinal tract
and metabolized before the active ingredients exert effects dir-
ectly on osteoblastic cells. In addition, HEP extract might con-
tain other substances that interfere with the biological actions
of the active ingredient on cell lines. Thus, a study of the
effects of the total extract of HEP in vitro might not be ideal.
Future studies are needed to identify the active ingredient(s)
in the HEP extract that are responsible for the osteoprotective
effects in OVX rats.
In summary, the present study clearly demonstrates the
in vivo efficacy of using HEP extract to prevent OVX-
induced increase in bone turnover rate and to restore the loss
of trabecular bone architecture in OVX rats. Moreover, the in
vitro data indicated that the observed increase in trabecular
bone area and decrease in bone turnover rate by HEP extract
in OVX rats might be mediated by its direct action of stimulat-
ing bone formation and inhibiting bone resorption. Both
in vivo and in vitro studies provide evidence that HEP extract
is a promising alternative and complementary therapeutic
agent for the management of postmenopausal osteoporosis.
However, in order to develop HEP extract in the international
scientific community as an alternative regime for the treatment
of bone diseases, more research will be needed to identify the
active ingredients in HEP extract as well as the mechanism that
mediates the action of HEP extract in vivo.
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